Microbix Biosystems Inc T.MBX

Alternate Symbol(s): MBXBF

Healthcare Biotechnology

Microbix Biosystems Inc. develops and commercializes biological and technological solutions for human health and wellbeing. It enables the commercialization of diagnostic assays by making a range of critical ingredients and devices for the global diagnostics industry, notably antigens for immunoassays and its laboratory quality assessment products (QAPs) that support clinical lab proficiency testing, enable assay development and validation, or help ensure the quality of clinical diagnostic workflows. Its segments include development, manufacturing and sales of products relating to the medical diagnostics industry, namely antigens as test ingredients, quality assessment products to help ensure the accuracy of test workflows and viral transport medium to enable collection of patient test samples and, and development and commercialization of novel and proprietary products or technologies, such as Kinlytic. Its Kinlytic urokinase is a biologic thrombolytic drug used to treat blood clots.

TSX:MBX - Post by User

Microbix Biosystems Inc

Bullboard Posts

Comment by rjc7on Jan 11, 2016 9:58pm

109 Views

Post# 24448504

RE:RE:RE:RE:RE:RE:RE:Someone Needs To Read The Balance Sheet

Of course they need debt! A growing business needs cash to expand or you sit and let others eat you up. MBX was less than a $4million company when I first started investing with no pipeline and a very reduced core business. They are now a $10million company, and one of the leading suppliers of diagnostic biological tests in the world. They OWN Urokinase outright and once partnered (which they will), will outstrip the current drug TPA as it performs much better and safer in clot busting and catheter clearance. Any successful company carries debt. It's managing that debt that becomes critical and they are managing their debt without issue.

Bullboard Posts

Quantum eMotion leaps by 20 per cent after Becton Dickinson deal